Heart failure & cardiomyopathiesResearch article
Performance and Safety of the Extravascular Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy
- international, multicenter, interventional trial
- analysis derived from the Pivotal EV-ICD Study
Authors' conclusion
In patients with HCM, the EV-ICD demonstrated high defibrillation success and a safety profile similar to what was observed in non-HCM patients.
Study context
- Population
- Patients with guideline-based indications for implantable cardioverter-defibrillator (ICD) therapy undergoing attempted EV-ICD placement, classified by a diagnosis of hypertrophic cardiomyopathy (HCM) at baselineunderwent attempted EV-ICD placement, 41 [13%] with HCM · HCM 41
- Participants
- 316 patients
- Comparison
- HCM vs non-HCM patients receiving the EV-ICD
- HCMn = 41
- Outcome
- Successful defibrillation testing (main efficacy endpoint)
- Follow-up
- At implantation
Main finding
As reported in the abstract
P = 1.00
Further findings
Implantation success rate
P = 0.47
Appropriate ICD therapy · mean follow-up of 30.6 ± 8.5 months · HCM therapy was shock for ventricular fibrillation
log-rank P = 0.20
Safety
Inappropriate ICD therapies · mean follow-up of 30.6 ± 8.5 months
log-rank P = 0.80
System- and procedure-related major complications (main safety endpoint) · through 3 years of follow-up
log-rank P = 0.44
Original publication
Performance and Safety of the Extravascular Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy. JACC Clin Electrophysiol. Published 11 March 2026. doi:10.1016/j.jacep.2026.01.052
Summarised from the published abstract; every number is checked against it